PMID- 35478259 OWN - NLM STAT- MEDLINE DCOM- 20220718 LR - 20221014 IS - 1752-8062 (Electronic) IS - 1752-8054 (Print) IS - 1752-8054 (Linking) VI - 15 IP - 7 DP - 2022 Jul TI - Serum cytokines to predict systemic lupus erythematosus clinical and serological activity. PG - 1676-1686 LID - 10.1111/cts.13283 [doi] AB - We aimed to explore the role of interleukin (IL)-6, interferon-gamma (IFNgamma), IL-10, and tumor necrosis factor (TNF) as predictors of systemic lupus erythematosus (SLE) clinical and serological activity, and their correlation with the treatment received. We performed a retrospective analysis of 77 patients with SLE according to the 2012 Systemic Lupus International Collaborative Clinics (SLICC) criteria. The outcomes were serological activity (SA), active disease (AD), complete remission (CR), the low-disease activity state (LDAS), and immunosuppressive treatment. SA was present in 17.1%, AD in 17.3%, CR in 13%, and LDAS in 64.9% of patients. IL-6 values were higher in patients in SA, in AD, in those receiving steroids alone, and in patients without CR or LDAS (p < 0.05). IFNgamma was associated with anti-double stranded DNA (dsDNA) antibodies positivity and immunosuppression, whereas IL-10 values were higher in patients with CR (p < 0.05). The IL6-IFN product was able to predict anti-double stranded DNA (anti-dsDNA) antibodies positivity (area under the receiver operating characteristic curve [AUC-ROC] = 0.705, 95% confidence interval [CI] 0.563-0.847), SA (AUC-ROC = 0.720, 95% CI 0.542-0.899), AD (AUC-ROC = 0.701, 95% CI 0.520-0.882), steroid treatment (AUC-ROC = 0.751, 95% CI 0.622-0.879), and the absence of LDAS (AUC-ROC = 0.700, 95% CI 0.558-0.834). The IL6-IFN/IL10 ratio predicted AD (AUC-ROC = 0.742, 955 CI 0.540-0.944), steroid treatment (AUC-ROC = 0.721, 95% CI 0.572-0.870), and the absence of LDAS (AUC-ROC = 0.694, 95% CI 0.536-0.853). In conclusion, IL-6, IL-10, and IFNgamma might help to assess SLE serological and clinical activity. Their combination in the IL-6-IFN product and the IL-6xIFN to IL-10 ratio results in novel tools to determine and predict SA, AD, and LDAS. Prompt detection of SLE activity might allow a rapid intervention to avoid established or chronic damage. CI - (c) 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. FAU - Moreno-Torres, Victor AU - Moreno-Torres V AUID- ORCID: 0000-0002-9798-4514 AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Castejon, Raquel AU - Castejon R AUID- ORCID: 0000-0002-9765-0303 AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Martinez-Urbistondo, Maria AU - Martinez-Urbistondo M AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Gutierrez-Rojas, Angela AU - Gutierrez-Rojas A AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Vazquez-Comendador, Jose AU - Vazquez-Comendador J AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Tutor, Pablo AU - Tutor P AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Duran-Del Campo, Pedro AU - Duran-Del Campo P AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Mellor-Pita, Susana AU - Mellor-Pita S AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Rosado, Silvia AU - Rosado S AUID- ORCID: 0000-0001-8131-819X AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Vargas-Nunez, Juan-Antonio AU - Vargas-Nunez JA AD - Systemic Autoimmune Diseases Unit, Internal Medicine Service, IDIPHIM (University Hospital Puerta de Hierro Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220504 PL - United States TA - Clin Transl Sci JT - Clinical and translational science JID - 101474067 RN - 0 (Antibodies, Antinuclear) RN - 0 (Cytokines) RN - 0 (Interleukin-6) RN - 130068-27-8 (Interleukin-10) RN - 9007-49-2 (DNA) SB - IM MH - *Antibodies, Antinuclear/blood MH - *Cytokines/blood MH - DNA/immunology MH - Humans MH - Interleukin-10/blood MH - Interleukin-6/blood MH - *Lupus Erythematosus, Systemic/blood/drug therapy/immunology MH - Retrospective Studies PMC - PMC9283738 COIS- The authors declared that no competing interests for this work. EDAT- 2022/04/29 06:00 MHDA- 2022/07/19 06:00 PMCR- 2022/07/01 CRDT- 2022/04/28 05:51 PHST- 2022/03/22 00:00 [revised] PHST- 2022/02/13 00:00 [received] PHST- 2022/03/31 00:00 [accepted] PHST- 2022/04/29 06:00 [pubmed] PHST- 2022/07/19 06:00 [medline] PHST- 2022/04/28 05:51 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - CTS13283 [pii] AID - 10.1111/cts.13283 [doi] PST - ppublish SO - Clin Transl Sci. 2022 Jul;15(7):1676-1686. doi: 10.1111/cts.13283. Epub 2022 May 4.